HealthEquity (HQY) Stock May Be 44% Cheap As Cash Flow Leads
HealthEquity stock has returned 55.6% over the past three years, yet its valuation signals do not line up, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while earnings-based multiples suggest the shares are on the expensive side.
- Over the past three years, HealthEquity has returned 55.6%, which puts more weight on whether today’s price can be backed by the company’s future cash flows rather than by recent share price momentum alone.
- Expectations for continued cash flow generation from HealthEquity’s health savings account platform can support the DCF view, while any pressure on fee margins or account growth may limit how much investors are willing to pay on earnings multiples.
- With a value score of 4 out of 6 on Simply Wall St’s checks, HealthEquity screens as a mixed picture rather than a clear bargain or an obviously expensive stock.
The issue now is whether the 43.6% discount suggested by the DCF intrinsic value estimate offers enough cushion against the more cautious signal coming from market multiples for HealthEquity.
Find out why HealthEquity's -0.0% return over the last year is lagging behind its peers.
Is HealthEquity Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach values HealthEquity by projecting the cash it could return to shareholders and discounting that back to today. On this model, HealthEquity’s latest twelve month free cash flow sits at about $265.7 million, with analysts and internal estimates assuming that cash generation increases over time rather than declines.
Feeding those projections into a 2 Stage Free Cash Flow to Equity framework produces an estimated intrinsic value of about $173 per share. Compared with the current market price, that indicates a 43.6% discount, which is why the DCF output points to HealthEquity as undervalued even though earnings multiples appear higher.
Overall, the Discounted Cash Flow valuation indicates that HealthEquity stock appears undervalued at today’s price.
Our Discounted Cash Flow (DCF) analysis suggests HealthEquity is undervalued by 43.6%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Has HealthEquity Run Too Far on Earnings?
For HealthEquity, the P/E ratio is a useful yardstick because the market often focuses on earnings when assessing established platform businesses. The stock currently trades at about 35.4x earnings, which sits above the broader healthcare sector average of roughly 26.0x but below the peer group average of about 39.5x. That positions HealthEquity between sector and closer peers and suggests investors already ascribe a premium to its earnings profile versus the wider industry.
Simply Wall St’s fair P/E estimate for HealthEquity is about 26.0x, which is lower than the current market multiple. This gap indicates investors are paying more per dollar of earnings than the model implies would be reasonable after factoring in the company’s size, margins and risk profile. While not extreme, that premium points to expectations already embedded in the share price, leaving less room for disappointment if future earnings do not track those assumptions.
On the P/E yardstick, HealthEquity stock screens as overvalued relative to the level that would typically be justified by its fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
The HealthEquity Narrative: What Would Justify Today's Price?
For HealthEquity, Simply Wall St Narratives sit between the DCF signal and the earnings multiples by explaining which paths for growth, margins and earnings would need to occur for the stock to be worth significantly more or less than its current market price. Rather than providing a single output from a ratio or model, they describe the future assumptions behind that figure so you can track whether those conditions hold over time on the Community page.
If you have a number driven view on where HealthEquity's growth, margins and execution go from here, add your Narrative to the Simply Wall St community and put your case on record.
This is a chance to share your thinking on HealthEquity's valuation assumptions and then watch how that thesis holds up as new results and data arrive.
Do you think there's more to the story for HealthEquity? Head over to our Community to see what others are saying!
The Bottom Line
For HealthEquity, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while earnings multiples flag the stock as overvalued versus typical sector benchmarks. That split mostly comes down to cash flow strength and timing on one side, and how much investors are already paying for expected growth on the other. With broader valuation checks sitting in the middle, the key question from here is whether HealthEquity can deliver the cash flow and earnings profile that keeps justifying a premium multiple rather than turning that apparent DCF discount into a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com